Medifast, Inc. (MED) | Investment Case

1. Company Snapshot

1.a. Company Description

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands.It markets its products through point-of-sale transactions over ecommerce platform.

The company was founded in 1980 and is headquartered in Baltimore, Maryland.

Show Full description

1.b. Last Insights on MED

Medifast's recent performance has been hindered by a decline in customer acquisition, leading to a dip in revenue year-over-year. The company's efforts to enhance coach productivity have been prioritized, but the impact of this initiative remains to be seen. Furthermore, the introduction of GLP-1 medication has caused a vicious flywheel effect, resulting in a significant decline in demand and coach losses. This has forced Medifast to reposition itself as a GLP-1 adjacent business, but the effectiveness of this strategy is still uncertain.

1.c. Company Highlights

Last Price	10.88
Change Percentage	2.35%
Open	10.7
Previous Close	10.63
Market Cap ( Millions)	120
Volume	440725
Year High	15.46
Year Low	9.22
M A 50	10.45
M A 200	12.19

FCF Yield	1.04%
Dividend Yield	0.00%
ROE	-8.89%
Debt / Equity	8.44%
Net Debt / EBIDTA	-4987.48%
Price To Book	0.6
Price Earnings Ratio	-6.4
Price To FCF	95.74
Price To sales	0.31
EV / EBITDA	32.37

2. Medifast's Q4 2025 Earnings: A Challenging Quarter Amidst Strategic Transformation

Medifast reported a revenue of $75.1 million for Q4 2025, representing a 36.9% year-over-year decline, primarily due to a 40.6% decrease in active earning coaches to approximately 16,100. However, the company achieved a 6.2% year-over-year growth in revenue per active earning coach to $4,664, marking the first positive growth since Q2 2022. The loss per share was $1.65, impacted by a $12.1 million non-cash valuation allowance. Excluding this allowance, the loss per share was $0.55, which was better than analyst estimates of -$0.76. Gross profit decreased 40.9% to $52.1 million, with a gross profit margin of 69.4%, while SG&A expense decreased 31.5% to $59.9 million.

Publication Date: Feb -20

                                    📋 Highlights
                                    Revenue Decline:
                                                Q4 2025 revenue fell 36.9% to $75.1M, primarily due to a 40.6% drop in active earning coaches to 16,100.
Coach Productivity Growth:
                                                Revenue per active coach rose 6.2% YoY to $4,664, the first positive growth since Q2 2022.
Loss Per Share:
                                                Net loss widened to $1.65/share, driven by a $12.1M non-cash valuation allowance; adjusted loss was $0.55/share.
Gross Profit Margin:
                                                Declined to 69.4% ($52.1M) despite a 31.5% reduction in SG&A expenses to $59.9M.
Future Guidance:
                                                2026 revenue projected at $270–300M, with a loss per share of $1.55–$2.75, reflecting strategic investments in metabolic health.

                                

Operational Highlights and Strategic Focus

The company is undergoing a significant transformation, shifting its focus towards metabolic health with a clinically proven system and coach-led model. This strategic shift is accompanied by investments in new product lines and research. According to CEO Dan Chard, this transition is expected to drive growth and improve productivity levels throughout 2026. The launch of a new product line is anticipated to be a key growth driver.

Guidance and Outlook

For Q1 2026, Medifast expects revenue to range from $65 million to $80 million, with a loss per share of $0.15 to $0.70. For the full year 2026, the company projects revenue between $270 million and $300 million, with a loss per share of $1.55 to $2.75. Analysts estimate a revenue decline of 9.6% for the next year. The company ended 2025 with $167.3 million in cash, cash equivalents, and investment securities, and no debt, providing a solid financial foundation for its strategic initiatives.

Valuation and Future Prospects

With a P/S Ratio of 0.3 and an EV/EBITDA of 30.41, the market appears to have factored in the challenges Medifast is facing. The company's ROE and ROIC are currently negative, at -8.89% and -6.5%, respectively. However, the expected improvements in earnings in 2027 and beyond, driven by the new product line and sustained productivity levels, could potentially lead to a revaluation of the stock. The working capital is expected to be over $140 million at December 31, 2026, further supporting the company's financial health and strategic execution.

3. NewsRoom

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Medifast, Inc. (NYSE: MED)

Apr -14

Source: prnewswire.com

Medifast's New Product Pipeline: Key Catalyst for Comeback?

Apr -07

Source: zacks.com

Medifast (NYSE:MED) CEO Acquires $178,724.58 in Stock

Mar -28

Source: defenseworld.net

Medifast Announces Cooperation Agreement with Steamboat Capital

Mar -20

Source: businesswire.com

Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients

Feb -20

Source: businesswire.com

Medifast Q4 Earnings Call Highlights

Feb -19

Source: defenseworld.net

Medifast Q4 Loss Wider Than Expected, Revenues Decline 37% Y/Y

Feb -18

Source: zacks.com

Medifast (MED) Reports Q4 Loss, Beats Revenue Estimates

Feb -17

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Weight Loss, Weight Management and Healthy Living Products

Expected Growth: 8.5%

Medifast's 8.5% growth in Weight Loss, Weight Management and Healthy Living Products is driven by increasing health awareness, rising obesity rates, and growing demand for convenient, at-home weight loss solutions. Strong brand recognition, expanding distribution channels, and innovative product offerings also contribute to the company's growth momentum.

7. Detailed Products

Medifast Meals

Pre-packaged, portion-controlled meals designed to support weight loss and overall health

Optavia Fuelings

Nutritionally-balanced, portion-controlled snacks and meals designed to support optimal health and wellness

Medifast Bars

Nutritionally-balanced, portion-controlled bars designed to support weight loss and overall health

Medifast Shakes

Nutritionally-balanced, portion-controlled shakes designed to support weight loss and overall health

Optavia Coach

Personalized coaching and support services designed to help individuals achieve their health and wellness goals

Optavia Community

Online community and support platform designed to connect individuals with similar health and wellness goals

8. Medifast, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Medifast's meal replacement products face moderate threat from substitutes, including fresh food, nutrition supplements, and other weight loss programs.

Bargaining Power Of Customers

Medifast's customers have limited bargaining power due to the company's strong brand reputation and lack of direct competition.

Bargaining Power Of Suppliers

Medifast's suppliers have limited bargaining power due to the company's large scale of operations and diversified supply chain.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry, including regulatory hurdles and significant capital investments required to establish a similar business model.

Intensity Of Rivalry

The weight loss industry is highly competitive, with many established players, including Nutrisystem, Jenny Craig, and Weight Watchers, which increases the intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	9.85%
Debt Cost	3.95%
Equity Weight	90.15%
Equity Cost	9.99%
WACC	9.39%
Leverage	10.93%

11. Quality Control: Medifast, Inc. passed 8 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Weyco

A-Score: 6.4/10

Value: 7.1

Growth: 5.9

Quality: 7.1

Yield: 10.0

Momentum: 3.0

Volatility: 5.0

1-Year Total Return ->

H&R Block

A-Score: 6.3/10

Value: 7.8

Growth: 6.0

Quality: 6.7

Yield: 7.0

Momentum: 1.5

Volatility: 8.7

1-Year Total Return ->

Ethan Allen

A-Score: 6.1/10

Value: 6.8

Growth: 3.8

Quality: 6.5

Yield: 10.0

Momentum: 2.5

Volatility: 7.0

1-Year Total Return ->

Carriage Services

A-Score: 5.6/10

Value: 5.2

Growth: 5.9

Quality: 5.7

Yield: 2.0

Momentum: 7.0

Volatility: 8.0

1-Year Total Return ->

Mister Car Wash

A-Score: 4.2/10

Value: 4.4

Growth: 7.4

Quality: 5.4

Yield: 0.0

Momentum: 2.5

Volatility: 5.7

1-Year Total Return ->

Medifast

A-Score: 3.6/10

Value: 5.5

Growth: 2.2

Quality: 5.1

Yield: 3.0

Momentum: 0.5

Volatility: 5.3

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

24.50%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

9.39%

Medifast, Inc. - US58470H1014

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on MED

1.c. Company Highlights

Higher Yield

Better Quality

Cheaper

Earnings Miss

Revenues Beats

Weak Momentum

Earnings Beats

Revenues Miss

Higher Growth

Average Quality

Average Growth

Fairly Valued

Lower Growth

Stable Momentum

Medium Volatility

2. Medifast's Q4 2025 Earnings: A Challenging Quarter Amidst Strategic Transformation

Operational Highlights and Strategic Focus

Guidance and Outlook

Valuation and Future Prospects

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Weight Loss, Weight Management and Healthy Living Products

Expected Growth: 8.5%

7. Detailed Products

Medifast Meals

Optavia Fuelings

Medifast Bars

Medifast Shakes

Optavia Coach

Optavia Community

8. Medifast, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Medifast, Inc. passed 8 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

10.88$

Current Price

10.88$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA